TELA Bio Statistics
Total Valuation
TELA Bio has a market cap or net worth of $112.26 million. The enterprise value is $137.95 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TELA Bio has 39.39 million shares outstanding. The number of shares has increased by 14.27% in one year.
| Current Share Class | 39.39M |
| Shares Outstanding | 39.39M |
| Shares Change (YoY) | +14.27% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 7.69% |
| Owned by Institutions (%) | 27.88% |
| Float | 26.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.02 |
| Forward PS | 1.22 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.62
| Current Ratio | 2.62 |
| Quick Ratio | 1.69 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.52 |
Financial Efficiency
Return on equity (ROE) is -342.03% and return on invested capital (ROIC) is -52.29%.
| Return on Equity (ROE) | -342.03% |
| Return on Assets (ROA) | -40.63% |
| Return on Capital (ROIC) | -52.29% |
| Revenue Per Employee | $302,419 |
| Profits Per Employee | -$182,921 |
| Employee Count | 227 |
| Asset Turnover | 0.98 |
| Inventory Turnover | 1.53 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.65% in the last 52 weeks. The beta is 1.00, so TELA Bio's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | -48.65% |
| 50-Day Moving Average | 2.85 |
| 200-Day Moving Average | 4.02 |
| Relative Strength Index (RSI) | 48.37 |
| Average Volume (20 Days) | 216,896 |
Short Selling Information
The latest short interest is 285,027, so 0.72% of the outstanding shares have been sold short.
| Short Interest | 285,027 |
| Short Previous Month | 335,908 |
| Short % of Shares Out | 0.72% |
| Short % of Float | 1.06% |
| Short Ratio (days to cover) | 1.28 |
Income Statement
In the last 12 months, TELA Bio had revenue of $68.65 million and -$41.52 million in losses. Loss per share was -$1.69.
| Revenue | 68.65M |
| Gross Profit | 47.27M |
| Operating Income | -45.62M |
| Pretax Income | -40.30M |
| Net Income | -41.52M |
| EBITDA | -44.71M |
| EBIT | -45.62M |
| Loss Per Share | -$1.69 |
Full Income StatementBalance Sheet
The company has $17.30 million in cash and $42.99 million in debt, giving a net cash position of -$25.69 million or -$0.65 per share.
| Cash & Cash Equivalents | 17.30M |
| Total Debt | 42.99M |
| Net Cash | -25.69M |
| Net Cash Per Share | -$0.65 |
| Equity (Book Value) | -6.27M |
| Book Value Per Share | -0.25 |
| Working Capital | 27.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$45.12 million and capital expenditures -$930,000, giving a free cash flow of -$46.05 million.
| Operating Cash Flow | -45.12M |
| Capital Expenditures | -930,000 |
| Free Cash Flow | -46.05M |
| FCF Per Share | -$1.17 |
Full Cash Flow StatementMargins
Gross margin is 68.86%, with operating and profit margins of -66.45% and -60.49%.
| Gross Margin | 68.86% |
| Operating Margin | -66.45% |
| Pretax Margin | -60.49% |
| Profit Margin | -60.49% |
| EBITDA Margin | -65.13% |
| EBIT Margin | -66.45% |
| FCF Margin | n/a |
Dividends & Yields
TELA Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.27% |
| Shareholder Yield | -14.27% |
| Earnings Yield | -36.99% |
| FCF Yield | -41.02% |
Analyst Forecast
The average price target for TELA Bio is $9.25, which is 224.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.25 |
| Price Target Difference | 224.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 26.92% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TELA Bio has an Altman Z-Score of -8.84 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.84 |
| Piotroski F-Score | 1 |